Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Young-Hak Kim

Showing results (1-10 of 672) with videos related to

Pageof 68
Sort By:
The New England Journal of Medicine|March 12, 2019
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung CancerYoung-Hak Kim
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2016
Gefitinib Plus Pemetrexed As First-Line Treatment in Patients With Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor MutationsYoung Hak Kim
Journal of Thoracic Disease|October 18, 2016
Dual inhibition of BRAF and MEK in BRAF-mutated metastatic non-small cell lung cancerYoung Hak Kim
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 22, 2016
Prophylactic Cranial Irradiation for Extensive-Stage Small Cell Lung CancerYoung Hak Kim
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 18, 2011
How should we use bevacizumab in patients with non-small cell lung cancer?Young Hak Kim, Michiaki Mishima
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 15, 2017
Successful Osimertinib Rechallenge after Severe Osimertinib-Induced HepatotoxicityHironori Yoshida, Young Hak Kim
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 23, 2015
Maintenance Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor after First-Line Chemotherapy in Mutation-Positive Non-Small-Cell Lung CancerYoung Hak Kim, Michiaki Mishima
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|April 21, 2018
Reply to the letter to the editor by Saito regarding the article "In vivo validation of mathematically derived fractional flow reserve for assessing haemodynamics of coronary tandem lesions"Jihoon Kweon, Young-Hak Kim
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2016
Consolidation Chemotherapy After Concurrent Chemoradiotherapy in Patients With Stage III Non-Small-Cell Lung CancerYoung Hak Kim, Michiaki Mishima
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 23, 2015
Relevance of platinum sensitivity in patients with relapsed or refractory small-cell lung cancerYoung Hak Kim, Michiaki Mishima
Pageof 68

Showing results (1-10 of 672) with videos related to

Sort By:
Pageof 68
The New England Journal of Medicine|March 12, 2019
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung CancerYoung-Hak Kim
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2016
Gefitinib Plus Pemetrexed As First-Line Treatment in Patients With Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor MutationsYoung Hak Kim
Journal of Thoracic Disease|October 18, 2016
Dual inhibition of BRAF and MEK in BRAF-mutated metastatic non-small cell lung cancerYoung Hak Kim
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 22, 2016
Prophylactic Cranial Irradiation for Extensive-Stage Small Cell Lung CancerYoung Hak Kim
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 18, 2011
How should we use bevacizumab in patients with non-small cell lung cancer?Young Hak Kim, Michiaki Mishima
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 15, 2017
Successful Osimertinib Rechallenge after Severe Osimertinib-Induced HepatotoxicityHironori Yoshida, Young Hak Kim
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 23, 2015
Maintenance Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor after First-Line Chemotherapy in Mutation-Positive Non-Small-Cell Lung CancerYoung Hak Kim, Michiaki Mishima
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|April 21, 2018
Reply to the letter to the editor by Saito regarding the article "In vivo validation of mathematically derived fractional flow reserve for assessing haemodynamics of coronary tandem lesions"Jihoon Kweon, Young-Hak Kim
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2016
Consolidation Chemotherapy After Concurrent Chemoradiotherapy in Patients With Stage III Non-Small-Cell Lung CancerYoung Hak Kim, Michiaki Mishima
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 23, 2015
Relevance of platinum sensitivity in patients with relapsed or refractory small-cell lung cancerYoung Hak Kim, Michiaki Mishima
Pageof 68